Drug Trial Radar · NCT04185246
A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Nov 4, 2019
Primary completion
Jul 1, 2020
Study completion Jul 1, 2020
Sponsor
- Lead sponsor
- Trust Bio-sonics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- StatPlus,Inc.
- First posted
- Dec 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular (LV) chamber and to improve the delineation of the LV endocardial border. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of NH002.
Conditions
- Cardiac Disease
Interventions
NH002 (Perflutren Lipid Microspheres) Injectable SuspensionDrug
NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
EchocardiogramDiagnostic test
Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-lead ECGsTime frame: From pre-injection to 60 minutes post injection
- Body TemperatureTime frame: From pre-injection to 120 minutes post injection
- Heart RateTime frame: From pre-injection to 120 minutes post injection
- Respiratory RateTime frame: From pre-injection to 120 minutes post injection
- Blood PressureTime frame: From pre-injection to 120 minutes post injection
- Thrombin Time (TT) and Activated Partial Thromboplastin Time (aPTT)Time frame: From pre-injection to 240 minutes post-injection
- Cardiac Troponin ITime frame: pre-injection and 240 minutes post-injection
- Oxygen Saturation by Pulse Oximetry (SpO2)Time frame: From pre-injection to 120 minutes post-injection
- Rate of Any Potential Adverse Allergic ReactionTime frame: From pre-injection to 240 minutes post-injection
- Cardiac Troponin TTime frame: pre-injection and 240 minutes post-injection
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Taipei Mackay Memorial Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.